US FDA Outlines Streamlined Development Path For Targeted Therapies
But reminds sponsors that more trials could be ordered post-approval, which may be important in face of evidence that tissue-agnostic cancer therapies are not always equally effective.
You may also be interested in...
Agency officials and oncologists debate considerations where a data package overwhelms non-responders in favor of a tissue-agnostic indication.
New oncologics bring CDER’s novel agent approvals count to 53 for the year.
FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.